Key result
16-protein plasma score identifies CKD progression in Latino adults with T2D.
Why the study?
Plasma proteomic risk scores show promise for predicting CKD progression, but existing models have largely been developed in populations that underrepresent Latino individuals.
Does a plasma proteomic risk score predict CKD progression in Latino adults with type 2 diabetes?
Observational (n=70)
Does a plasma proteomic risk score predict CKD progression in Latino adults with type 2 diabetes?
A novel 16-protein plasma risk score can identify CKD progression in Latino adults with type 2 diabetes, addressing a gap in population-specific risk models.
Answers are grounded in this paper and cite their sources.
Should not yet alter CKD monitoring in Latino adults with diabetes; extends proteomic approaches to an underrepresented group but remains hypothesis-generating.
Introduction and Objective: Chronic kidney disease (CKD) affects ~10% of adults worldwide, with diabetes as a major driver. Although plasma proteomic risk scores have shown promise for predicting CKD progression, these models have largely been developed in populations that underrepresent Latino individuals. We aimed to develop a plasma proteomic risk score for CKD progression in adults with type 2 diabetes (T2D) from El Banco por Salud, a Latino biobank. Methods: Seventy adults with T2D (31 progressors, 39 non-progressors) were studied. CKD progression was defined using individual-level linear regression of urine albumin-to-creatinine ratio (ACR) over time; positive slopes indicated progression. Plasma proteomics (5,415 proteins; Olink Explore HT) and Least Absolute Shrinkage and Selection Operator (LASSO) logistic regression were used to derive a proteomic risk score as a weighted sum of normalized protein expression values. Results: LASSO regression identified a set of 16 proteins associated with CKD progression (EML1, PARM1, ROR2, PIWIL4, TPGS2, BCAT2, CNTF, IDI2, KIR3DL1, TTN, TXLNB, THBD, IGF2R, PRAP1, RNASET2, and STC2), which together comprised the plasma proteomic risk score. Progressors and non-progressors were similar in BMI (32.3 ± 6.7 vs. 32.1 ± 7.1 kg/m2), eGFR (85.6 ± 26.9 vs. 82.8 ± 19.7 mL/min/1.73 m2), and blood pressure (systolic: 137.7 ± 19.2 vs. 133.6 ± 18.1 mmHg; diastolic: 81.0 ± 7.4 vs. 77.6 ± 7.3 mmHg). Progressors had higher serum creatinine (1.1 ± 0.6 vs. 0.8 ± 0.2 mg/dL, P<0.05) and elevated urine ACR (1595 ± 1851 vs. 32 ± 62 mg/g, P<0.05). Progressors also tended to be younger (55.7 ± 13.3 vs. 61.5 ± 10.8 years), have higher HbA1c (9.1 ± 2.1 vs. 8.2 ± 1.5%), and include a greater proportion of males (58.1% vs. 35.9%), although these differences did not reach statistical significance. Conclusion: We developed a 16-protein risk score that identifies CKD progression in Latino adults with T2D, highlighting the importance of population relevant proteomic risk models.
No takes yet. Share an insight, caveat, or question.
COLETTA et al. (2026) conducted an observational in Chronic kidney disease progression in type 2 diabetes (n=70). Plasma proteomic risk score (16 proteins) vs. Non-progressors was evaluated on CKD progression (positive slope of urine albumin-to-creatinine ratio over time). A 16-protein plasma risk score was developed to identify CKD progression in Latino adults with type 2 diabetes, with progressors having higher baseline urine ACR.
Synapse has enriched 10 related papers. Consider them for comparative context: